Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
| Fonds de la Recherche en Santé du Québec | OTHER_GOV |
| St. Justine's Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the concentration-effect relationship of inhaled milrinone after prophylactic administration in cardiac surgical patients with preoperative pulmonary hypertension undergoing cardiopulmonary bypass.
Milrinone elimination will be verify with blood and urine samples analysis.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Inhaled milrinone 5 mg | Experimental | Inhaled milrinone 5 mg(as for the injectable solution) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Inhaled milrinone 5 mg | Drug | Inhaled milrinone 5 mg (as for the injectable solution) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Study the elimination rate of milrinone administered by inhalation | up to 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Demonstrate the presence or absence of hemodynamic and echographic effects observed after inhalation of milrinone | hemodynamic values evaluated will be: central venous pressure, systolic and diastolic pulmonary pressure, wedge, cardiac output, cardiac frequency, systolic and diastolic pressure, SaO2, EtCO2. Patient will also have arterial and venous gaz. Echographic values will be evaluated to see the cardiac fonction: left and right ventricular systolic and diastolic function and valvular function. |
Not provided
Inclusion Criteria:
Patients scheduled for elective cardiac surgery under CPB
High risk patients: NYHA class II-III
Preoperative diagnostic of pulmonary hypertension:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrée Denault, MD PhD FRCPC | Montreal Heart Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Montreal Heart Institute | Montreal | Quebec | Canada |
Not provided
| ID | Term |
|---|---|
| D006976 | Hypertension, Pulmonary |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D020105 | Milrinone |
| ID | Term |
|---|---|
| D000676 | Amrinone |
| D000631 | Aminopyridines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D011725 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 15 min after the of study drug administration |
| Confirmation of the safety of inhaled milrinone | Verification of the absence of deleterious effects on cardiac output and systemic arterial pressure. | 24 hours after cardiac surgery |
| Determination of the efficacy of inhaled milrinone in the treatment of pulmonary hypertension | Efficacy in the treatment of pulmonary hypertension is defined as a reduction of the mean pulmonary pressure of 10-20 % | 15 min after end of milrinone administration |
| D002318 |
| Cardiovascular Diseases |
| Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |